FIELD: organic chemistry; medical chemistry; oncology.
SUBSTANCE: invention relates to the field of radiopharmaceuticals intended for use as theranostic agents for diagnostics and therapy of tumors expressing on HER2 receptors. Disclosed is a compound for producing a complex with a radionuclide label for theranostics of tumors with hyperexpression of epidermal growth factor type 2 (HER2) of general formula ADAPT6-(SSSG)3-ABD035-GSSC-DOTAGA and a complex comprising a compound according to claim 1 with radionuclide mark, which is 177Lu radionuclide.
EFFECT: wider range of theranostic agents for selective targeting and penetration into pathogenic tumor tissues, with optimal characteristics for targeted radionuclide therapy of tumors with hyperexpression of epidermal growth factor type 2 (HER2).
2 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING THE STATUS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR HER2/NEU IN THE MAIN TUMOR NODE IN BREAST CANCER PATIENTS | 2021 |
|
RU2762317C1 |
METHOD FOR PREDICTION OF HER2/NEU EPIDERMAL GROWTH FACTOR RECEPTOR STATUS IN MAIN TUMOR NODE IN BREAST CANCER PATIENTS | 2022 |
|
RU2779751C1 |
METHOD OF PREDICTING THE STATUS OF EPIDERMAL GROWTH FACTOR RECEPTOR HER2/NEU IN METASTATIC AXILLARY LYMPH NODES IN PATIENTS WITH BREAST CANCER | 2023 |
|
RU2803857C1 |
PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
METHOD OF BREAST CANCER DIAGNOSTICS WITH HER2/NEU HYPEREXPRESSION | 2022 |
|
RU2800818C1 |
METHOD FOR PREDICTION OF EPIDERMAL GROWTH FACTOR RECEPTOR STATUS HER2/NEU IN PRIMARY TUMOUR IN PATIENTS WITH BREAST CANCER | 2021 |
|
RU2766248C1 |
METHOD FOR PREDICTING STATUS OF EPIDERMAL GROWTH FACTOR HER2/NEU IN METASTATIC LYMPH NODES IN BREAST CANCER PATIENTS | 2021 |
|
RU2757960C1 |
METHOD FOR RADIONUCLIDE DIAGNOSING OPERABLE BREAST CANCER WITH OVEREXPRESSION OF HER2/NEU | 2019 |
|
RU2702294C1 |
METHOD FOR RADIONUCLIDEAN DIAGNOSTICS OF SECONDARY EDEMATOUS-INFILTRATIVE FORM OF BREAST CANCER WITH OVEREXPRESSION OF HER2/NEU USING RECOMBINANT ADDRESS MOLECULES DARPIN9_29 | 2019 |
|
RU2700109C1 |
METHOD FOR EVALUATING NEOADJUVANT SYSTEMIC THERAPY OF BREAST CANCER WITH HER2/NEU OVEREXPRESSION | 2020 |
|
RU2737996C1 |
Authors
Dates
2024-09-06—Published
2023-11-14—Filed